サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1382567

すくみ足の世界市場、予測（～2030年）

Freeze of Gait Market Research Report Forecast till 2030
出版日: | 発行: Market Research Future | ページ情報: 英文 82 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
すくみ足の世界市場、予測（～2030年）
出版日: 2023年11月15日
発行: Market Research Future
ページ情報: 英文 82 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のすくみ足の市場規模は、予測期間にCAGRで4.86%の成長が見込まれています。すくみ足の急増は市場拡大の重大な促進要因の1つです。

Parkinson's Foundationの調査によると、現在米国では約100万人がパーキンソン病（PD）と共に生活しており、この数は2030年までに120万人に増加します。

地域の考察

北米の市場規模は2022年に4億8,000万米ドルに達し、調査期間にCAGRで5.17%の成長が予測されています。

欧州市場は、医療の利用の増加や最先端の治療薬への関心の高まり、老年人口の拡大により、2番目に大きなシェアを占める見込みです。

アジア太平洋市場は、2023年～2030年にCAGRで6.03%の成長が予測されています。

当レポートでは、世界のすくみ足市場について調査分析し、市場力学、地域とセグメントの分析、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
    • パーキンソン病とその他の関連疾患の流行
    • 老年人口の増加
    • 研究開発への投資の増加
  • 抑制要因
    • 厳しい規制要件
  • 機会
    • 技術の進歩と新製品の発売

第5章 市場要因の分析

  • バリューチェーン分析
    • 研究開発、設計
    • 製造
    • 流通、マーケティング、販売
    • 販売後モニタリング
  • ポーターのファイブフォース分析モデル
  • すくみ足市場に対するCOVID-19の影響の分析
    • 概要
    • 原材料と製品のコストに対する影響
    • 製品の入手可能性に対する影響
    • 選択的処置に対する影響
    • サプライチェーンに対する影響

第6章 世界のすくみ足市場：タイプ別

  • 概要
  • 経口ドーパミン作動薬
  • ウェアラブルデバイス、歩行補助デバイス
  • 深部脳刺激
  • その他

第7章 世界のすくみ足市場：エンドユーザー別

  • 概要
  • 病院
  • 診療所
  • その他

第8章 世界のすくみ足市場：地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • その他の地域
    • 中東
    • アフリカ
    • ラテンアメリカ

第9章 競合情勢

  • 概要
  • 競合ベンチマーキング
  • すくみ足市場における主な成長戦略
  • すくみ足市場における開発数の主要企業
  • 主な発展と成長戦略
    • パートナーシップと提携
  • 主要企業の売上の分析
    • 売上・営業利益
  • 主要企業の研究開発の分析

第10章 企業プロファイル

  • VIATRIS INC.
  • GONDOLA MEDICAL TECHNOLOGIES SA
  • USTEP
  • GYENNO TECHNOLOGIES CO., LTD.
  • MEDEXO ROBOTICS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD
  • WALK WITH PATH
  • BEATS MEDICAL LIMITED
  • AGILITAS

第11章 付録

図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019-2030 (USD MILLION)
  • TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019-2030 (USD MILLION)
  • TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019-2030 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019-2030 (USD MILLION)
  • TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET
  • TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET
  • TABLE 65 PARTNERSHIP & COLLABORATIONS
  • TABLE 66 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED
  • TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS
  • TABLE 69 USTEP: PRODUCTS OFFERED
  • TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED
  • TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED
  • TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
  • TABLE 74 WALK WITH PATH: PRODUCTS OFFERED
  • TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED
  • TABLE 76 AGILITAS: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL FREEZE OF GAIT MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: GLOBAL FREEZE OF GAIT MARKET
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL FREEZE OF GAIT MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL FREEZE OF GAIT MARKET
  • FIGURE 9 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2022 & 2030 (USD MILLION)
  • FIGURE 10 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, SEGMENT SHARE, 2022
  • FIGURE 11 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2022 & 2030 (USD MILLION)
  • FIGURE 12 GLOBAL FREEZE OF GAIT MARKET, BY END USER, SEGMENT SHARE, 2022
  • FIGURE 13 GLOBAL FREEZE OF GAIT MARKET, BY REGION, 2022 & 2030 (USD MILLION)
  • FIGURE 14 GLOBAL: FREEZE OF GAIT MARKET SHARE (%), BY REGION, 2022
  • FIGURE 15 NORTH AMERICA: FREEZE OF GAIT MARKET SHARE (%), BY REGION 2022
  • FIGURE 16 EUROPE: FREEZE OF GAIT MARKET SHARE, BY REGION 2022 (%)
  • FIGURE 17 ASIA PACIFIC: FREEZE OF GAIT MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 18 REST OF THE WORLD: FREEZE OF GAIT MARKET SHARE, BY COUNTRY, 2022 (%)
  • FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN FREEZE OF GAIT MARKET
  • FIGURE 21 MAJOR PLAYERS SALES & OPERATING INCOME, 2022
  • FIGURE 22 MAJOR PLAYERS R&D EXPENDITURE, 2022
  • FIGURE 23 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 VIATRIS INC.: SWOT ANALYSIS
  • FIGURE 25 GONDOLA MEDICAL TECHNOLOGIES SA: SWOT ANALYSIS
  • FIGURE 26 GYENNO TECHNOLOGIES CO., LTD.: SWOT ANALYSIS
  • FIGURE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
  • FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
目次
Product Code: MRFR/HC/10578-HCR

Market Overview

Freeze of Gait Market is projected exhibit a compound annual growth rate (CAGR) of 4.86% during the forecast period. The Rising transcendence of freeze of gait is one of the critical driving components for market advancement.

Parkinson's contamination is an issue of the central tactile framework that causes inadvertent or wild turns of events, like solidness, shaking, and issue with coordination and balance. These aftereffects generally begin steadily and annihilate once again the long run. This could achieve inconvenience walking and talking. Freezing of gait (Fog) is perhaps of the most debilitating motor aftereffect in Parkinson's affliction (PD) patients. Freezing of gait is a peculiar gait plan that prompts an unforeseen inability to begin or walk.

According to data appropriated in Nature Journal, in the year 2022, Fog affected around half of Parkinson's ailment patients and 80% of state-of-the-art Parkinson's disorder patients. According to the Parkinson's Foundation, at the present time around a million people in the US are living with Parkinson's disease (PD), and it is surveyed that this number will rise to 1.2 million by 2030.

Market Segmentation

Deep brain stimulation, wearable technology, walking aids, oral dopaminergic medications, and other products are included in the Freeze of Gait Market categorization based on type.

The Freeze of Gait Market is segmented according to end users, which encompasses clinics, hospitals, and other establishments.

Regional Insights

The North America Freeze of Gait market is supposed to represent USD 0.48 billion out of 2022 and is supposed to show a 5.17% CAGR during the review time frame. This is credited to the business presence of significant vital participant, rising FDA endorsement, and expanding mindfulness about the prescription and treatments, rising pervasiveness of Parkinson sickness in the region drive the regional market development during the forecast time frame.

Europe Freeze of Gait market is supposed to represent the second-biggest piece of the pie because of the rising medical care use, rising interest for cutting edge therapeutics, and expanding geriatric populace led to gamble of Parkinson illness related freeze of gait which drive the development of freeze gait in Europe region.

Openness to trend setting innovation for sickness finding, the rising geriatric populace inclined to Freeze of Gait is driving up interest for powerful therapy and therapeutics and expanding mindfulness about the freeze of gait.

The Asia-Pacific freeze of gait market is supposed to develop at a CAGR of 6.03% from 2023 to 2030. This is because of elements, for example, rising clinical office, expanding government drive for freeze gait treatment, presence of enormous patient pool of Parkinson illness related with freeze of gait are decidedly influence on the development of freeze of gait market in Asia-Pacific region. The Rest of the World incorporates the Middle East, Africa, and Latin America.

Market Overview

Key Companies in the Freeze of Gait Market Include Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), and Ustep (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF PARKINSON'S DISEASE AND OTHER RELATED DISEASES
    • 4.2.2 GROWING GERIATRIC POPULATION
    • 4.2.3 INCREASING INVESTMENT IN R&D
  • 4.3 RESTRAINTS
    • 4.3.1 STRINGENT REGULATORY REQUIREMENTS
  • 4.4 OPPORTUNITIES
    • 4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D AND DESIGNING
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION, MARKETING, AND SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET
    • 5.3.1 OVERVIEW
    • 5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS
    • 5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS
    • 5.3.4 IMPACT ON ELECTIVE PROCEDURE
    • 5.3.5 IMPACT ON SUPPLY CHAIN

6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 ORAL DOPAMINERGIC MEDICATION
  • 6.3 WEARABLE AND WALKING AID DEVICES
  • 6.4 DEEP BRAIN STIMULATION
  • 6.5 OTHERS

7 GLOBAL FREEZE OF GAIT MARKET, BY END USER

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.3 CLINICS
  • 7.4 OTHERS

8 GLOBAL FREEZE OF GAIT MARKET, BY REGION

  • 8.1 NORTH AMERICA
    • 8.1.1 US
    • 8.1.2 CANADA
  • 8.2 EUROPE
    • 8.2.1 GERMANY
    • 8.2.2 FRANCE
    • 8.2.3 UK
    • 8.2.4 ITALY
    • 8.2.5 SPAIN
    • 8.2.6 REST OF EUROPE
  • 8.3 ASIA-PACIFIC
    • 8.3.1 CHINA
    • 8.3.2 INDIA
    • 8.3.3 JAPAN
    • 8.3.4 AUSTRALIA
    • 8.3.5 SOUTH KOREA
    • 8.3.6 REST OF ASIA-PACIFIC
  • 8.4 REST OF THE WORLD
    • 8.4.1 MIDDLE EAST
    • 8.4.2 AFRICA
    • 8.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPETITIVE BENCHMARKING
  • 9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET
  • 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET
  • 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 9.5.1 PARTNERSHIP & COLLABORATIONS
  • 9.6 MAJOR PLAYERS SALES ANALYSIS
    • 9.6.1 SALES & OPERATING INCOME
  • 9.7 MAJOR PLAYERS R&D ANALYSIS

10 COMPANY PROFILES

  • 10.1 VIATRIS INC.
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 FINANCIAL OVERVIEW
    • 10.1.3 PRODUCTS OFFERED
    • 10.1.4 KEY DEVELOPMENTS
    • 10.1.5 SWOT ANALYSIS
    • 10.1.6 KEY STRATEGIES
  • 10.2 GONDOLA MEDICAL TECHNOLOGIES SA
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 FINANCIAL OVERVIEW
    • 10.2.3 PRODUCTS OFFERED
    • 10.2.4 KEY DEVELOPMENTS
    • 10.2.5 SWOT ANALYSIS
    • 10.2.6 KEY STRATEGIES
  • 10.3 USTEP
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 FINANCIAL OVERVIEW
    • 10.3.3 PRODUCTS OFFERED
    • 10.3.4 KEY DEVELOPMENTS
    • 10.3.5 KEY STRATEGIES
  • 10.4 GYENNO TECHNOLOGIES CO., LTD.
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 FINANCIAL OVERVIEW
    • 10.4.3 PRODUCTS OFFERED
    • 10.4.4 KEY DEVELOPMENTS
    • 10.4.5 SWOT ANALYSIS
    • 10.4.6 KEY STRATEGIES
  • 10.5 MEDEXO ROBOTICS
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 FINANCIAL OVERVIEW
    • 10.5.3 PRODUCTS OFFERED
    • 10.5.4 KEY DEVELOPMENTS
    • 10.5.5 KEY STRATEGIES
  • 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 FINANCIAL ANALYSIS
    • 10.6.3 PRODUCTS OFFERED
    • 10.6.4 KEY DEVELOPMENTS
    • 10.6.5 SWOT ANALYSIS
    • 10.6.6 KEY STRATEGIES
  • 10.7 SUN PHARMACEUTICAL INDUSTRIES LTD
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 FINANCIAL OVERVIEW
    • 10.7.3 PRODUCTS OFFERED
    • 10.7.4 KEY DEVELOPMENTS
    • 10.7.5 SWOT ANALYSIS
    • 10.7.6 KEY STRATEGIES
  • 10.8 WALK WITH PATH
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 FINANCIAL OVERVIEW
    • 10.8.3 PRODUCTS OFFERED
    • 10.8.4 KEY DEVELOPMENTS
    • 10.8.5 KEY STRATEGIES
  • 10.9 BEATS MEDICAL LIMITED
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 FINANCIAL OVERVIEW
    • 10.9.3 PRODUCTS OFFERED
    • 10.9.4 KEY DEVELOPMENTS
    • 10.9.5 KEY STRATEGIES
  • 10.10 AGILITAS
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 FINANCIAL OVERVIEW
    • 10.10.3 PRODUCTS OFFERED
    • 10.10.4 KEY DEVELOPMENTS
    • 10.10.5 KEY STRATEGIES

11 APPENDIX

  • 11.1 REFERENCES
  • 11.2 RELATED REPORTS